Nonadherence to antiretroviral therapy in HIV-positive patients in Costa Rica

AIDS Patient Care and STDs

Volumn 18, Issue 5, 2004, Pages 297-304

  Stout, Brian Douglas ^a   Leon, Maria Paz ^b   Niccolai, Linda M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hosp Mexico   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; AGED; ARTICLE; COSTA RICA; FEMALE; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; REGRESSION ANALYSIS; RISK FACTOR; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COSTA RICA; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MOTIVATION; NEEDS ASSESSMENT; OUTPATIENT CLINICS, HOSPITAL; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; TRANSPORTATION;

EID: 2642517262     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729104323076034     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Maisels L, Steinberg J, Tobias C. An investigation of why eligible patients do not receive HAART. AIDS Patient Care STDs 2001;15:185-191.
3. Staszewski S, Harberl A, Gute P, et al. Nevirapine/ didanosine/ lamivudine once daily in HIV-1 infected intravenous drug users. Antiviral Ther 1998;3(Suppl 4):55-56.
4. Molina JM, Ferchal F, Rancinan C, et al. Once daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602.
5. Friedland GH, Andrews LA. Adherence to antiretroviral therapy. AIDS Rev 2001;3:111-120.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002;34:1115-1121.
8. Sale M, Sheiner LB, Volberding P, et al. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993:54: 556-566.
9. Altice FL, Friedland GH. The era of adherence in antiretroviral therapy. Ann Intem Med 1998;129:503-505.
10. Acurcio FA, Guimaraes MD. Utilization of prescribed drugs by HIV infected individuals: qualitative approach. Rev Saude Publica 1999;33:73-84.
11. Knobel H, Carmona A, Guelar A, et al. Adherence in patients treated with HAART: Influence in hospital admissions. Presented at the 13th International AIDS Conference. 2000, Durban.
12. Hogg R, Yip B, Chan K, et al. Non-adherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women. Presented at the 13th International AIDS Conferences 2000, Durban.
13. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 2002;14:309-318.
14. Ickovics JR, Cameron A, Zackin R, et al. Consequences and determinants of adherence: Results from adult AIDS clinical trials group protocol 370. Antivir Ther 2003;7:185-93.
15. Altice FL, Mostashari R. Friedland GH. Trust and acceptance of and adherence to antiretroviral therapy. J Acquired Immune Defic Syndrome 2001;28:47-58.
16. Kalichman SC, Ramachandran B, Catz S. Adherence to Combination Antiretroviral Therapies in HIV Patients on Low Health Literacy. J Gen Intern. Med 1999;14:267-273.
17. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquired Immune Defic Syndromes 2001;28:124-131.
18. Haddad M, Inch C, Glazier RH, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2000;(3):CD001442.
19. Sowell RL, Phillips KD, Seals BF, et al. HIV-infected women's experiences and beliefs related to AZT therapy during pregnancy. AIDS Patient Care and STDs. 2001;15:201-209.
20. Durante AJ, Bova CA, Fennie KP, et al. Home-based study of anti-HIV drug regimen adherence among HIV-infected women: Feasibility and preliminary results. AIDS Care 2003;15:103-115.
21. Gallant J, Block D. Adherence to antiretroviral regimens in HIV-infected patients: Results of a survey among physicians and patients. J Int Assoc Physicians AIDS Care 1998;4:32-35.
22. Laws MB, Wilson IB, Bowser DM, et a. Taking antiretroviral therapy for HIV infection: Learning from patients' stories. J Gen Intern Med 2000;15:848-858.
23. Muma RD, Ross MW, Parcel G, et al. Zidovudine adherence among individuals with HIV infection. AIDS Care 1995;7:439.
24. Singh N, Squier C, Sivek C, et al. Determinants of compliance with antiretroviral therapy in patients with HIV: Prospective assessment with implications for enhancing compliance. AIDS Care 1996;8:261.
25. Kastrissios H, Blaschke TF. Therapeutic implications of nonadherence with antiretroviral drug regimens. HIV Adv Res Ther 1998;8:24-28.
26. Belzer ME, Fuchs DN, Luftman GS, et al. Antiretroviral adherence issues among HIV positive adolescents and young adults. J Adolesc Health 1999;25: 316.
27. Pan American Health Organization. Country Health Profile: Costa Rica. 2001.
28. HIV/AIDS in Costa Rica and USAID Involvement. Report prepared for USAID by TvT Associates, Inc., under the Synergy Project, 2002.
29. Ickovics JR. Measures of adherence. Presented at the Adherence to New HIV Therapies: A Research Conference. 1997, Washington, D.C.